Werewolf Therapeutics (HOWL)
Develops conditionally activated cytokine and T-cell-engager therapies for cancer.
Something off on this page? Send us feedback.
Develops conditionally activated cytokine and T-cell-engager therapies for cancer, built around a platform that activates drug candidates in diseased tissue. With no approved products or product-sale revenue, development and financing depend on clinical progress, partners, licensing, and strategic transactions.
Develops conditionally activated cancer therapeutics through the PREDATOR protein-engineering platform, which uses masks and protease-cleavable linkers to keep cytokines and T-cell engagers inactive in peripheral tissue and activate them in diseased tissue, principally the tumor microenvironment. The approach is intended to retain potency while reducing systemic toxicity.
Centers its retained clinical portfolio on WTX-124, an IL-2 candidate for advanced solid tumors, and WTX-330, an IL-12 candidate for advanced and metastatic solid tumors; earlier INDUCER candidates target prostate, ovarian, and kidney cancers. Operates without approved products or product-sale revenue and is evaluating a sale, merger, asset sale, licensing, collaboration, or another strategic transaction. Further development depends on funding and partners, third-party manufacturing, clinical outcomes, and regulatory review.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Dec 19, 2025 | Wedbush | Downgrade | Target: — | Target: $1 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $22.0M · Total debt $0 · Total assets $24.2M · Shareholders' equity $16.3M
- Revenue
- $21.0M
- Operating income
- $8.5M
- Net income
- $3.7M
No dividends on record.
| Institutions | 22.36% | 10.86M shares | |
|---|---|---|---|
| 47 holders · as of Jun 30, 2026 | |||
| Insiders | 15.08% | 7.33M shares | |
| 3 holders · as of Sep 21, 2026 | |||
| Other | 62.56% | 30.41M shares | |
| remainder | |||
48.60M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Ansbert GadickeInsiderother: Former 10% Owner | 9.84% | 4.78M | filed Dec 4, 2025 |
Moll PeterInsider | 5.22% | 2.54M | filed Sep 21, 2026 |
Ra Capital Management, L.P.Institution | 4.91% | 2.39M | as of Jun 30, 2026 |
Balyasny Asset Management L.P.Institution | 3.68% | 1.79M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 2.51% | 1.22M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 7, 2026 | Luke Evnin | director | −107,429 | $0.3100 |
| Jul 6, 2026 | Luke Evnin | director | −35,770 | $0.3200 |
| Jun 29, 2026 | Luke Evnin | director | −157,084 | $0.3000 |
| Jun 17, 2026 | Ra Capital Management, L.P. | 10 percent owner | −416,911 | $0.3500 |
| Jun 16, 2026 | Ra Capital Management, L.P. | 10 percent owner | −149,625 | $0.3700 |
- Xilio Therapeutics
Closest platform rival in tumor-activated IL-12 and masked engagers.
- PDS Biotechnology
Tumor-targeted IL-12 contender across solid-tumor combination trials.
- BioNTech (ADR)
mRNA-encoded IL-2 pipeline challenger in multiple solid tumors.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Werewolf Therapeutics | $0.9767 | −0.54% | $47.7M | — | — | 2.3 | — |
| Xilio Therapeutics | $8.94 | −1.11% | $59.4M | — | — | 0.9 | +131.1% |
| PDS Biotechnology | $0.8438 | −7.27% | $50.9M | — | — | — | — |
| BioNTech (ADR) | $100.32 | −0.55% | $25.34B | — | — | 8.4 | −60.7% |
| Median | — | — | 4.7 | +35.2% |